ALDA Pharmaceuticals Corp.
OTC Bulletin Board : APCSF

ALDA Pharmaceuticals Corp.

June 23, 2009 19:27 ET

ALDA Decides Not to Proceed With Acquisition

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 23, 2009) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") announces that it has determined not to proceed with the proposed acquisition set out in the non-binding letter of intent described in the Company's news release dated February 23, 2009 and has therefore terminated the letter of intent.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTC BB under the symbol APCSF.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Diane Mann
    Distribution & Sales Contact
    (604) 657-0369
    Retail Sales
    Eastern Esthetics (ON, QU, NB, NS, PE, NL)
    (902) 450-2161
    Retail Sales
    LCN Canada - West (MB, SK, AB, BC, NW, YK)
    (780) 462-2580
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222